A5059023087- Vaccine Coverage and Hesitancy
- SARS-CoV-2 and COVID-19 Research
- Influenza Virus Research Studies
- Bacterial Infections and Vaccines
- Pneumonia and Respiratory Infections
- Respiratory viral infections research
- Health Systems, Economic Evaluations, Quality of Life
- Advanced Causal Inference Techniques
- COVID-19 Clinical Research Studies
- Statistical Methods in Clinical Trials
- Herpesvirus Infections and Treatments
- COVID-19 Impact on Reproduction
- Healthcare Policy and Management
- COVID-19 epidemiological studies
- Virology and Viral Diseases
- Pharmacovigilance and Adverse Drug Reactions
- Colorectal Cancer Screening and Detection
- Medication Adherence and Compliance
- Chronic Disease Management Strategies
- Heparin-Induced Thrombocytopenia and Thrombosis
- Statistical Methods and Bayesian Inference
- Peripheral Neuropathies and Disorders
- Viral Infections and Immunology Research
- Primary Care and Health Outcomes
- Global Cancer Incidence and Screening
Kaiser Permanente
2016-2025
Intermountain Healthcare
2021-2024
Atrium Health Wake Forest Baptist
2024
Vanderbilt University Medical Center
2024
Oakland Museum of California
2024
Yale University
2024
Hennepin County Medical Center
2024
Baystate Medical Center
2024
Baylor Scott & White Medical Center - Temple
2024
Intermountain Medical Center
2024
To determine the efficacy, safety and immunogenicity of heptavalent CRM197 pneumococcal conjugate vaccine against invasive disease caused by serotypes to effectiveness this clinical episodes otitis media.The Wyeth Lederle Heptavalent (PCV) was given infants at 2, 4, 6 12 15 months age in a double blind trial; 37,868 children were randomly assigned 1:1 receive either or meningococcus type C conjugate. The primary study outcome serotype. Other outcomes included overall impact on regardless...
The proportion of screening colonoscopic examinations performed by a physician that detect one or more adenomas (the adenoma detection rate) is recommended quality measure. However, little known about the association between this rate and patients' risks subsequent colorectal cancer (interval cancer) death.
Objective. To determine the effectiveness of Wyeth heptavalent pneumococcal conjugate vaccine against clinical and radiograph-confirmed pneumonia in children. Methods. The CRM197 (PCV) was given to infants at 2, 4, 6 12 15 months age a randomized, double blind trial. 1 Children were randomized receive either PCV (vaccine group) or meningococcal type C (control group). primary outcome this trial invasive disease. In addition children with diagnosis study population identified through review...
Safety surveillance of vaccines against COVID-19 is critical to ensure safety, maintain trust, and inform policy.To monitor 23 serious outcomes weekly, using comprehensive health records on a diverse population.This study represents an interim analysis safety data from Vaccine Datalink. The 10 162 227 vaccine-eligible members 8 participating US plans were monitored with administrative updated weekly supplemented medical record review for selected December 14, 2020, through June 26,...
In the United States, children receive five doses of diphtheria, tetanus, and acellular pertussis (DTaP) vaccine before 7 years age. The duration protection after DTaP is unknown.We assessed risk in California relative to time since fifth dose from 2006 2011. This period included a large outbreak 2010. We conducted case-control study involving members Kaiser Permanente Northern who were vaccinated with at 47 84 months compared confirmed by positive polymerase-chain-reaction (PCR) assay two...
Objectives: The objectives of this study were to provide estimates the prevalence and strength association between major depression chronic pain in a primary care population examine clinical burden associated with two conditions, singly together. Methods: A random sample Kaiser Permanente patients who visited clinic was mailed questionnaire assessing depressive disorder (MDD), pain, pain-related disability, somatic symptom severity, panic disorder, other anxiety, probable alcohol abuse,...
Context. The heptavalent pneumococcal conjugate vaccine (PCV) is recommended for infants to protect against invasive disease, but its impact on otitis might also have public health importance. Objective. To examine the of PCV incidence media, frequent media and tympanostomy tube procedures assess whether effectiveness wanes after age 24 months varies by race, sex or season. Design, setting patients.. From 1995 1998, 37 868 children at Kaiser Permanente in Northern California were randomized...
BackgroundThere are limited data on the effectiveness of vaccines against symptomatic coronavirus disease 2019 (Covid-19) currently authorized in United States with respect to hospitalization, admission an intensive care unit (ICU), or ambulatory emergency department urgent clinic.MethodsWe conducted a study involving adults (≥50 years age) Covid-19–like illness who underwent molecular testing for severe acute respiratory syndrome 2 (SARS-CoV-2). We assessed 41,552 admissions 187 hospitals...
CDC recommends that all persons aged ≥12 years receive a booster dose of COVID-19 mRNA vaccine ≥5 months after completion primary vaccination series and immunocompromised third dose.* Waning protection 2 doses has been observed during the period SARS-CoV-2 B.1.617.2 (Delta) variant predominance† (1-5), but little is known about durability 3 periods Delta or B.1.1.529 (Omicron) predominance. A test-negative case-control study design using data from eight VISION Network sites§ examined...
This article examines social and occupational disability associated with several DSM-IV mental disorders in a group of adult primary care outpatients.The subjects were 1,001 patients (aged 18-70 years) large health maintenance organization. Data on each patient's sociodemographic characteristics functional disability, including scores the Sheehan Disability Scale, collected at time medical visit. A structured diagnostic interview for current was then completed by professional over telephone...
To explore the association between maternal and paternal age risk of autism spectrum disorders (ASDs) in offspring.Historical birth cohort study.Kaiser Permanente (KP) Northern California.All singleton children born at KP from January 1, 1995, to December 31, 1999, were included study. We identified 593 who had ASD diagnoses (International Classification Diseases, Ninth Revision, Clinical Modification, code 299.0 or 299.8) recorded 2 more times outpatient databases before May 2005. These...
Estimates of COVID-19 mRNA vaccine effectiveness (VE) have declined in recent months (1,2) because waning induced immunity over time,* possible increased immune evasion by SARS-CoV-2 variants (3), or a combination these and other factors. CDC recommends that all persons aged ≥12 years receive third dose (booster) an ≥5 after receipt the second immunocompromised individuals primary dose.† A BNT162b2 (Pfizer-BioNTech) increases neutralizing antibody levels (4), three studies from Israel shown...
Adverse-event reports from North America have raised concern that the use of drugs for attention deficit–hyperactivity disorder (ADHD) increases risk serious cardiovascular events.
In February 2008, we alerted the Advisory Committee on Immunization Practices to preliminary evidence of a twofold increased risk febrile seizures after combination measles-mumps-rubella-varicella (MMRV) vaccine when compared with separate measles-mumps-rubella (MMR) and varicella vaccines. Now data twice as many recipients, our goal was reexamine seizure MMRV vaccine.Using 2000-2008 Vaccine Safety Datalink data, assessed fever visits among children aged 12 23 months MMR + We that vaccines...
Vaccination against pertussis during pregnancy is recommended to protect newborns, yet there limited information about the effectiveness of maternal tetanus toxoid, reduced diphtheria acellular (Tdap) vaccine before first infant dose diphtheria, and (DTaP) year life in infants who have received DTaP.In a retrospective cohort study born at Kaiser Permanente Northern California from 2010 2015, we estimated vaccination for protecting newborns 2 months accounting each DTaP dose.Among 148 981...
Immunocompromised persons, defined as those with suppressed humoral or cellular immunity resulting from health conditions medications, account for approximately 3% of the U.S. adult population (1). adults are at increased risk severe COVID-19 outcomes (2) and might not acquire same level protection mRNA vaccines do immunocompetent (3,4). To evaluate vaccine effectiveness (VE) among immunocompromised adults, data VISION Network* on hospitalizations persons aged ≥18 years COVID-19-like illness...
The efficacy of the BNT162b2 (Pfizer-BioNTech) vaccine against laboratory-confirmed COVID-19 exceeded 90% in clinical trials that included children and adolescents aged 5-11, 12-15, 16-17 years (1-3). Limited real-world data on 2-dose mRNA effectiveness (VE) persons 12-17 (referred to as this report) have also indicated high levels protection SARS-CoV-2 (the virus causes COVID-19) infection COVID-19-associated hospitalization (4-6); however, VE B.1.1.529 (Omicron) variant duration are...
To estimate the effectiveness of mRNA vaccines against moderate and severe covid-19 in adults by time since second, third, or fourth doses, age immunocompromised status.Test negative case-control study.Hospitals, emergency departments, urgent care clinics 10 US states, 17 January 2021 to 12 July 2022.893 461 (≥18 years) admitted one 261 hospitals 272 department 119 centers for covid-like illness tested SARS-CoV-2.The main outcome was waning vaccine with BNT162b2 (Pfizer-BioNTech) mRNA-1273...
Postauthorization monitoring of vaccines in a large population may detect rare adverse events not identified clinical trials such as Guillain-Barré syndrome (GBS), which has background rate 1 to 2 per 100 000 person-years.To describe cases and incidence GBS following COVID-19 vaccination assess the risk after for Ad.26.COV2.S (Janssen) mRNA vaccines.This cohort study used surveillance data from Vaccine Safety Datalink at 8 participating integrated health care systems United States. There...
The Omicron variant (B.1.1.529) of SARS-CoV-2, the virus that causes COVID-19, was first identified in United States November 2021, with BA.1 sublineage (including BA.1.1) causing largest surge COVID-19 cases to date. sublineages BA.2 and BA.2.12.1 emerged later by late April 2022, accounted for most cases.* Estimates vaccine effectiveness (VE) can be reduced newly emerging variants or evade vaccine-induced immunity (1), protection from previous SARS-CoV-2 infection unvaccinated persons (2),...
<h3>Importance</h3> Although colonoscopy is frequently performed in the United States, there limited evidence to support threshold values for physician adenoma detection rate as a quality metric. <h3>Objective</h3> To evaluate association between and risks of postcolonoscopy colorectal cancer related deaths. <h3>Design, Setting, Participants</h3> Retrospective cohort study 3 large integrated health care systems (Kaiser Permanente Northern California, Kaiser Southern Washington) with 43...
During June-October 2022, the SARS-CoV-2 Omicron BA.5 sublineage accounted for most of sequenced viral genomes in United States, with further diversification through November 2022.* Bivalent mRNA vaccines contain an ancestral strain component plus updated BA.4/BA.5 sublineages. On September 1, a single bivalent booster dose was recommended adults who had completed primary vaccination series (with or without subsequent doses), last administered ≥2 months earlier (1). 13-November 18, VISION...
Persons with moderate-to-severe immunocompromising conditions might have reduced protection after COVID-19 vaccination, compared persons without (1-3). On August 13, 2021, the Advisory Committee on Immunization Practices (ACIP) recommended that adults receive an expanded primary series of 3 doses mRNA vaccine. ACIP followed recommendations September 23, for a fourth (booster) dose and 1, 2022, new bivalent vaccine booster dose, containing components BA.4 BA.5 sublineages Omicron (B.1.1.529)...
On September 1, 2022, CDC's Advisory Committee on Immunization Practices (ACIP) recommended a single bivalent mRNA COVID-19 booster dose for persons aged ≥12 years who had completed at least monovalent primary series. Early vaccine effectiveness (VE) estimates among adults ≥18 showed receipt of provided additional protection against COVID-19-associated emergency department and urgent care visits hospitalizations compared with that in received only doses (1); however, insufficient time...